EU | pharmaphorum

EU

News

GBT claims EU approval for sickle cell drug Oxbryta

Global Blood Therapeutics' run of positive regulatory news for its oral sickle cell disease treatment Oxbryta has continued with an approval for the drug in Europe for patients aged over 12

News

AZ's lupus drug Saphnelo cleared in EU, challenging GSK's Be...

AstraZeneca's Saphnelo has become the first new drug to be approved to treat the autoimmune disease systemic lupus erythematosus (SLE) in the EU for more than 10 years.

News

Merck gets EU nod for Keytruda in adjuvant kidney cancer

Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, with the European Commission approving use of the drug

R&D

US vs EU: How can Europe translate home-grown innovation int...

We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United States.

News

Intercept's travails continue as it pulls NASH drug filing i...

Already scrambling to refile its obeticholic acid (OCA) drug for non-alcoholic steatohepatitis (NASH) after the FDA rejected it last year, Intercept Pharma was hoping for more luck in Europ

News

Roche, Blueprint's RET cancer drug Gavreto cleared in EU

Roche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers, after getting approval for Gavreto from the European Commission.

GBT claims EU approval for sickle cell drug Oxbryta

AZ's lupus drug Saphnelo cleared in EU, challenging GSK's Be...

Merck gets EU nod for Keytruda in adjuvant kidney cancer

US vs EU: How can Europe translate home-grown innovation int...

Intercept's travails continue as it pulls NASH drug filing i...

Roche, Blueprint's RET cancer drug Gavreto cleared in EU

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

EU

Editor's Picks